MyMedicalRecords Signs Patent License Agreement With Salutopia, a
Leading Patient Information EHR Provider
LOS ANGELES, CA and HOUSTON, TX--(Marketwired - Jun 25, 2014) -
MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary,
MyMedicalRecords, Inc. (collectively, "MMR"), and Salutopia, Inc.
jointly announced the signing of a patent license agreement. The
agreement calls for MMR to receive license fees based on a
percentage of the gross sales of Salutopia products and services
currently projected at more than $50,000,000 based on Salutopia's
sales pipeline. In exchange, Salutopia benefits from rights to
MMR's growing portfolio of U.S. health information technology
patents and all additional applications that are pending in the
United States. Salutopia is a leading Texas-based clinical data
aggregator and provider of content connecting disparate Electronic
Medical Record systems, practice management systems and patient
portals. The agreement gives Salutopia the ability to deliver its
products and services with MMR's licensed intellectual property
inside, while also allowing Salutopia to offer selected MMR
proprietary features and benefits from the MyMedicalRecords
Personal Health Record (PHR). The agreement also allows MMR to
offer selected proprietary products and services from
Salutopia.
The relationship gives MMR and its patented intellectual
property greater exposure to the healthcare IT vertical. As a
market leader of integrated clinical data aggregation, Salutopia
provides patients, providers and payers, including insurance
companies, hospital networks, MCOs, Home Health Care organizations,
ACOs (Accountable Care Organizations), IPAs (Independent Physicians
Associations), Health Information Exchanges, and others, seamless
interoperability of patient data across all Electronic Health
Record technology systems, simplifying interconnectivity between
diverse systems.
According to Fred Zolla, Chairman and Chief Strategy Officer for
Salutopia, "Incorporating MMR's licensed products in our current
service offerings ensures our clients a higher level of protection
and gives us an advantage over our competitors."
MMR's global health information technology patent portfolio
includes 12 issued U.S. patents: U.S. Patent Nos. 8,768,725,
8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287;
8,352,288; 8,498,883; 8,626,532; 8,645,161, and 8,725,537, in
addition to a recently issued Notice of Allowance from the United
States Patent and Trademark Office for U.S. Application Serial No.
13/082,896, which collectively include over 290 issued claims,
along with additional applications and continuation applications
pending. MMR also has received issued patents and has pending
applications in 11 other countries or regional authorities of
commercial interest including Australia, Canada, Singapore, New
Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and
Europe.
Using MMR's patented IP, Salutopia is planning on expanding
their patient portals to make it possible for patients to access,
collect and manage all their medical records, including
prescriptions, online in a secure and private manner. The service
will also achieve, individually and collectively, seamless
interoperability with one historic consolidated medical record for
patients and all their family members regardless of the number of
physicians and the technology on the other end of the PHR. Using
MMR's patented IP, Salutopia also provides patients, any number of
treating doctors, and other healthcare professionals (including
emergency room physicians and staff) access to complete, secure and
private medical information whenever and wherever it's needed from
anywhere in the world. The Salutopia patient portal can reduce
healthcare costs, eliminate unnecessary duplicate testing and
delays in obtaining treatment, as well as other wasteful and
potentially dangerous practices facing patients. Together, both
companies enable patients to be involved in their own healthcare
through modern communication and direct access to their complete
medical history.
About MMRGlobal: MMRGlobal, Inc., through its wholly-owned
operating subsidiary, MyMedicalRecords, Inc., provides secure and
easy-to-use online Personal Health Records ("PHRs") and electronic
safe deposit box storage solutions, serving consumers, healthcare
professionals, employers, insurance companies, financial
institutions, retail pharmacies, and professional organizations and
affinity groups. The MyMedicalRecords PHR enables individuals and
families to access their medical records and other important
documents, such as birth certificates, passports, insurance
policies and wills, anytime from anywhere using the Internet.
MyMedicalRecords is built on proprietary, patented technologies to
allow documents, images and voicemail messages to be transmitted
and stored in the system using a variety of methods, including fax,
phone, or file upload without relying on any specific electronic
medical record platform to populate a user's account. MMR's
professional offering, MMRPro, is designed to give physicians'
offices an easy and cost-effective solution to digitizing
paper-based medical records and sharing them with patients through
an integrated patient portal. Through its merger with Favrille,
Inc. in January 2009, MMR acquired intellectual property biotech
assets that include anti-CD20 antibodies and data and samples from
its FavId™/Specifid™ vaccine clinical trials for the treatment of
B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc.
visit www.mmrglobal.com. View demos and video tutorials of MMR's
products and services at www.mmrtheater.com. Follow us at
Facebook.com/MMRGlobal and Twitter.com/mmrglobal.
About Salutopia Salutopia, founded in 1995 and headquartered in
Houston, TX, is an industry leader in providers, patients and
insurance companies a reality. Salutopia leverages its rich
healthcare information technology experience to bring proprietary
solutions that redefine on-demand availability. To learn more about
Salutopia, visit www.salutopia.com.
Forward-Looking Statements All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property licenses, intellectual property
enforcement actions, infringement claims or litigation, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause MMR's actual results
to be materially different from historical results or from any
results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance.
Such statements are necessarily based on assumptions and estimates
and are subject to various risks and uncertainties, including those
relating to the possible invalidity of the underlying assumptions
and estimates and possible changes or developments in economic,
business, industry, market, legal and regulatory circumstances and
conditions and actions taken or omitted to be taken by third
parties, including customers, suppliers, business partners,
potential licensees, competitors and legislative, judicial and
other governmental authorities and officials. Factors that could
cause or contribute to such differences include, but are not
limited to: unexpected outcomes with respect to intellectual
property enforcement actions, claims of intellectual property
infringement and general intellectual property litigation; our
ability to maintain, develop, license, monetize and protect our
patent portfolio for both MMR's health IT and biotechnology
intellectual property assets in the U.S. and internationally; the
timing of milestone payments in connection with licensing our
intellectual property; our ability to establish and maintain
strategic relationships; changes in our relationships with our
licensees; the risk MMR's products are not adopted or viewed
favorably by the healthcare community and consumer retail market;
business prospects, results of operations or financial condition;
risks related to the current uncertainty and instability in
financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations;
the length of sales cycles and the installation process; the
market's acceptance of new product and service introductions;
competitive product offerings and promotions; changes in government
laws and regulations including the 2009 HITECH Act and changes in
Meaningful Use and the 2010 Affordable Care Act; future changes in
tax legislation and initiatives in the healthcare industry;
undetected errors in our products; the possibility of interruption
at our data centers; risks related to third party vendors; risks
related to obtaining and integrating third-party licensed
technology; risks related to a security breach by third parties;
risks associated with recruitment and retention of key personnel;
other litigation matters; uncertainties associated with doing
business internationally across borders and territories; and
additional risks discussed in MMR's filings with the Securities and
Exchange Commission. MMR is providing this information as of the
date of this release and, except as required by applicable law,
does not undertake any obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or otherwise.
CONTACTS MMRGlobal: Michael Selsman Public Communications Co.
(310) 922-7033
ms@publiccommunications.biz Salutopia: Amanda Zapp Managing
Director, Marketing and Communications ProActive Capital
Direct: 646.863.8998 Cell:
518.929.5280
azapp@proactivecapital.com